v3.26.1
Segment Information (Tables)
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Schedule of Segment Profit or Loss and Significant Segment Expenses Additional information about segment profit or loss and significant segment expenses is as follows:
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Direct R&D program expense
BHV-4157 (Troriluzole)$7,704 $14,245 $14,626 $28,033 
BHV-2000 (Taldefgrobep Alfa)5,730 8,045 15,062 14,229 
BHV-7000 & BHV-7010 (Kv7)13,845 31,172 33,578 62,744 
BHV-2100 & BHV-2110 (TRPM3 Antagonist)
(325)6,845 (530)23,594 
BHV-8000 (TYK2/JAK1)4,142 21,216 9,312 25,589 
BHV-1300 (IgG Degrader)9,861 11,732 11,003 20,352 
BHV-1310 (IgG Degrader)15 3,612 (19)4,686 
BHV-1400 (IgA Degrader)11,709 6,737 16,846 11,597 
BHV-1600 (β1-AR AAB Degrader)(288)1,806 (99)4,809 
BHV-1510 (TROP-2)
2,465 5,384 6,502 9,873 
BHV-1530 (FGFR3)2,211 15,393 3,410 18,569 
Other R&D program expense14 1,104 63 1,615 
Preclinical research programs R&D Expense
7,730 16,398 16,279 41,933 
R&D personnel expense (excluding share-based compensation)(1)
19,421 20,490 40,433 41,627 
R&D Share-based compensation expense
11,983 13,110 30,458 48,344 
G&A personnel expense (excluding share-based compensation)(1)
5,765 6,004 11,220 12,478 
G&A Share-based compensation expense
7,181 7,702 16,992 25,530 
Other segment items (2)
15,736 20,706 30,191 37,660 
Non-operating expense (income)12,021 (13,815)11,853 (14,308)
Provision for income taxes
391 261 663 870 
Segment net loss
137,311 198,147 267,843 419,824 
Reconciliation of profit or loss
Adjustments and reconciling items
— — — — 
Consolidated net loss
$137,311 $198,147 $267,843 $419,824 
(1)    Personnel expense includes employee payroll, bonus, and employee benefits for medical care, retirement, insurances and other.
(2)    Other segment items included in Segment net loss include unallocated non-program R&D expense, legal, accounting and other professional service fees, rent and utilities expense, depreciation, and other corporate expenses.